A phase II, randomized, open label trial of pre-operative (neoadjuvant) letrozole (Femara) vs. letrozole in combination with Avastin [bevacizumab] in post menopausal women with newly diagnosed operable breast cancer.

Trial Profile

A phase II, randomized, open label trial of pre-operative (neoadjuvant) letrozole (Femara) vs. letrozole in combination with Avastin [bevacizumab] in post menopausal women with newly diagnosed operable breast cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Letrozole
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 28 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 23 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top